CA2617090A1 — Hydrochlorides and hydrates of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)xanthine,their preparation and their use as medicaments
Assigned to Boehringer Ingelheim International GmbH · Expires 2007-02-08 · 19y expired
What this patent protects
The invention relates to salts of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-aminopiperidin-1-yl]xanthine represented by formula (I): (see formula I) with hydrochloric acid, and also to their enantiomers, mixtures thereof and hydrates thereof.
USPTO Abstract
The invention relates to salts of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-aminopiperidin-1-yl]xanthine represented by formula (I): (see formula I) with hydrochloric acid, and also to their enantiomers, mixtures thereof and hydrates thereof.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.